191 related articles for article (PubMed ID: 31358793)
1. Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease.
Carreras I; Aytan N; Choi JK; Tognoni CM; Kowall NW; Jenkins BG; Dedeoglu A
Sci Rep; 2019 Jul; 9(1):10972. PubMed ID: 31358793
[TBL] [Abstract][Full Text] [Related]
2. Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential.
Angelopoulou E; Piperi C
Neuromolecular Med; 2019 Sep; 21(3):227-238. PubMed ID: 31313064
[TBL] [Abstract][Full Text] [Related]
3. Modulatory Effects of Fingolimod (FTY720) on the Expression of Sphingolipid Metabolism-Related Genes in an Animal Model of Alzheimer's Disease.
Jęśko H; Wencel PL; Lukiw WJ; Strosznajder RP
Mol Neurobiol; 2019 Jan; 56(1):174-185. PubMed ID: 29687345
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease.
Aytan N; Choi JK; Carreras I; Brinkmann V; Kowall NW; Jenkins BG; Dedeoglu A
Sci Rep; 2016 Apr; 6():24939. PubMed ID: 27117087
[TBL] [Abstract][Full Text] [Related]
5. Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer's disease.
Jung Y; Lopez-Benitez J; Tognoni CM; Carreras I; Dedeoglu A
Brain Res; 2023 Jan; 1799():148171. PubMed ID: 36410428
[TBL] [Abstract][Full Text] [Related]
6. Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling.
Mike EV; Makinde HM; Der E; Stock A; Gulinello M; Gadhvi GT; Winter DR; Cuda CM; Putterman C
Front Immunol; 2018; 9():2189. PubMed ID: 30319641
[TBL] [Abstract][Full Text] [Related]
7. Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Leßmann V; Kartalou GI; Endres T; Pawlitzki M; Gottmann K
J Neural Transm (Vienna); 2023 Aug; 130(8):1003-1012. PubMed ID: 37014414
[TBL] [Abstract][Full Text] [Related]
8. Oral Administration of Thioflavin T Prevents Beta Amyloid Plaque Formation in Double Transgenic AD Mice.
Sarkar S; Raymick J; Ray B; Lahiri DK; Paule MG; Schmued L
Curr Alzheimer Res; 2015; 12(9):837-46. PubMed ID: 26510980
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis.
Bascuñana P; Möhle L; Brackhan M; Pahnke J
Drugs R D; 2020 Sep; 20(3):197-207. PubMed ID: 32696271
[TBL] [Abstract][Full Text] [Related]
10. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
11. FTY720 Attenuates Infection-Induced Enhancement of Aβ Accumulation in APP/PS1 Mice by Modulating Astrocytic Activation.
McManus RM; Finucane OM; Wilk MM; Mills KHG; Lynch MA
J Neuroimmune Pharmacol; 2017 Dec; 12(4):670-681. PubMed ID: 28620801
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive Intestinal Peptide Decreases β-Amyloid Accumulation and Prevents Brain Atrophy in the 5xFAD Mouse Model of Alzheimer's Disease.
Korkmaz OT; Ay H; Aytan N; Carreras I; Kowall NW; Dedeoglu A; Tuncel N
J Mol Neurosci; 2019 Jul; 68(3):389-396. PubMed ID: 30498985
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod Rescues Memory and Improves Pathological Hallmarks in the 3xTg-AD Model of Alzheimer's Disease.
Fagan SG; Bechet S; Dev KK
Mol Neurobiol; 2022 Mar; 59(3):1882-1895. PubMed ID: 35031916
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod Affects Transcription of Genes Encoding Enzymes of Ceramide Metabolism in Animal Model of Alzheimer's Disease.
Jęśko H; Wencel PL; Wójtowicz S; Strosznajder J; Lukiw WJ; Strosznajder RP
Mol Neurobiol; 2020 Jun; 57(6):2799-2811. PubMed ID: 32356173
[TBL] [Abstract][Full Text] [Related]
15. Gastrodin alleviates memory deficits and reduces neuropathology in a mouse model of Alzheimer's disease.
Hu Y; Li C; Shen W
Neuropathology; 2014 Aug; 34(4):370-7. PubMed ID: 24661139
[TBL] [Abstract][Full Text] [Related]
16. Glial Sphingosine-Mediated Epigenetic Regulation Stabilizes Synaptic Function in
Yin P; Cai Y; Cui T; Berg AJ; Wang T; Morency DT; Paganelli PM; Lok C; Xue Y; Vicini S; Wang T
J Neurosci; 2023 Oct; 43(42):6954-6971. PubMed ID: 37669862
[TBL] [Abstract][Full Text] [Related]
17. Lipid transporter Spns2 promotes microglia pro-inflammatory activation in response to amyloid-beta peptide.
Zhong L; Jiang X; Zhu Z; Qin H; Dinkins MB; Kong JN; Leanhart S; Wang R; Elsherbini A; Bieberich E; Zhao Y; Wang G
Glia; 2019 Mar; 67(3):498-511. PubMed ID: 30484906
[TBL] [Abstract][Full Text] [Related]
18. SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease.
Brunner D; Flunkert S; Neddens J; Duller S; Scopes DIC; Treherne JM; Hutter-Paier B
Neurosci Lett; 2017 Nov; 660():96-102. PubMed ID: 28917978
[TBL] [Abstract][Full Text] [Related]
19. Central effects of fingolimod.
Cruz VT; Fonseca J
Rev Neurol; 2014 Aug; 59(3):121-8. PubMed ID: 25030072
[TBL] [Abstract][Full Text] [Related]
20. Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer's Disease.
Bascuñana P; Brackhan M; Möhle L; Wu J; Brüning T; Eiriz I; Jansone B; Pahnke J
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
